filmov
tv
AAV Services for Gene Therapy - Virtual Event
Показать описание
Ginkgo's AAV Services for Gene Therapy: Integrated solutions across capsid, payload, and cell line engineering for manufacturing.
The STRIVE platform was built to address three major challenges: pre-existing immunity, tissue tropism, and manufacturability. With the recent acquisition of StrideBio, Ginkgo can now bring the STRIVE capsid engineering platform to our customers supported by the power of our industry-leading synthetic biology Foundry.
The existing STRIVE capsids are backed by a wealth of performance data, including studies in large animal models. A range of capsids are ready to go for partners to match to their desired indication or application.
Additional capsids in earlier stages of development are differentiated with in vivo or ex vivo data to show enhanced tissue tropism or potency relative to their parental backgrounds. Consider capsids specialized for the CNS, heart, muscle, liver, or even ex vivo targets such as T-cells.
In Ginkgo's Foundry, these proprietary capsid technologies are only the beginning. Our extensive capacity for high-throughput engineering of proteins and regulatory elements can enable the ambitions of our partners across the gene therapy space.
Learn more at
The STRIVE platform was built to address three major challenges: pre-existing immunity, tissue tropism, and manufacturability. With the recent acquisition of StrideBio, Ginkgo can now bring the STRIVE capsid engineering platform to our customers supported by the power of our industry-leading synthetic biology Foundry.
The existing STRIVE capsids are backed by a wealth of performance data, including studies in large animal models. A range of capsids are ready to go for partners to match to their desired indication or application.
Additional capsids in earlier stages of development are differentiated with in vivo or ex vivo data to show enhanced tissue tropism or potency relative to their parental backgrounds. Consider capsids specialized for the CNS, heart, muscle, liver, or even ex vivo targets such as T-cells.
In Ginkgo's Foundry, these proprietary capsid technologies are only the beginning. Our extensive capacity for high-throughput engineering of proteins and regulatory elements can enable the ambitions of our partners across the gene therapy space.
Learn more at
0:54:26
AAV Services for Gene Therapy - Virtual Event
0:04:31
VectorBuilder Inc. | Adeno-Associated Virus (AAV) Packaging Services #genetherapy #customcloning
0:54:19
AAV-mediated gene therapy approach: Ovid Therapeutics
0:52:00
Pre-clinical AAV production and optimization: Not as easy as it looks! | GenScript
0:02:22
AAV Based Gene Therapy - How AAV Gene Transfer Works - Basics of AAV Gene Therapy - BOC Sciences
0:15:27
TheraPEAK™ SfAAV™ Medium – the next step in AAV production
0:02:32
Quick Q&A with AI Marvin｜What is AAV and Gene Therapy
0:05:12
Cyagen and Neurophth Enter AI-AAV Collaboration for Ophthalmic Gene Therapy
0:58:30
AAV Vector Shedding Assay—Best Practices in Clinical Gene Therapy Method Development
0:07:00
1) Adeno Associated Virus (AAV) - An Introduction
0:34:43
Immunogenicity of AAV Vectors and Transgenes - Roland Herzog
0:01:33
why choose AAV for eye disease? | Episode 1
0:02:12
Measuring Quality Attributes for Gene Therapies: Empty vs Full Viral Vector Capsids
0:25:59
Advancing AAV: Novel Synthesis and Sequencing Solutions for Gene Therapy Research
0:47:03
How LV and AAV Transfection Platforms will Shape the Future of Gene Therapy Manufacturing
0:18:38
Solutions for gene therapy using a deeper analytical characterization of AAV vector development
0:23:32
AAV-Based Gene Therapy | Catenion Webinar Series
0:06:30
Cell line development and AAV: Pioneers of gene therapy
0:38:48
Accelerating AAV-based Gene Therapy Development: One-stop Shop Experience from VectorBuilder
0:39:53
2019 FAST Science Summit, AAV GeneTherapy, Dr. Jim Wilson, UPenn and John Crowley, Amicus
0:57:22
AAV & Lentiviral Gene Therapies with Sio Gene Therapies' Dr. Pavan Cheruvu
0:34:40
Federico Mingozzi: Assessing and modulating immune responses to AAV vectors in humans
0:07:17
2) Adeno Associated Virus (AAV) - Production and Modification of AAV
0:35:50
End-to-end CDMO Services: Reinforcing and Accelerating the Development of Cell and Gene Therapy
Комментарии